IE81157B1 - Use of sertindole for the treatment of schizophrenia - Google Patents
Use of sertindole for the treatment of schizophreniaInfo
- Publication number
- IE81157B1 IE81157B1 IE105190A IE105190A IE81157B1 IE 81157 B1 IE81157 B1 IE 81157B1 IE 105190 A IE105190 A IE 105190A IE 105190 A IE105190 A IE 105190A IE 81157 B1 IE81157 B1 IE 81157B1
- Authority
- IE
- Ireland
- Prior art keywords
- sertindole
- rats
- neurones
- compound
- treatment
- Prior art date
Links
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 title description 23
- 229960000652 sertindole Drugs 0.000 title description 22
- 238000011282 treatment Methods 0.000 title description 12
- 201000000980 schizophrenia Diseases 0.000 title description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000000561 anti-psychotic effect Effects 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 40
- 229960003638 dopamine Drugs 0.000 abstract description 20
- 210000004515 ventral tegmental area Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 210000002569 neuron Anatomy 0.000 abstract description 15
- 230000000903 blocking effect Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 241001573498 Compacta Species 0.000 abstract description 5
- 210000004556 brain Anatomy 0.000 abstract description 5
- 210000003523 substantia nigra Anatomy 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 8
- 229960004170 clozapine Drugs 0.000 description 8
- 208000009132 Catalepsy Diseases 0.000 description 7
- 206010047853 Waxy flexibility Diseases 0.000 description 7
- XRXDAJYKGWNHTQ-UHFFFAOYSA-N quipazine Chemical compound C1CNCCN1C1=CC=C(C=CC=C2)C2=N1 XRXDAJYKGWNHTQ-UHFFFAOYSA-N 0.000 description 7
- 229950002315 quipazine Drugs 0.000 description 7
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 6
- 206010042008 Stereotypy Diseases 0.000 description 6
- 229940025084 amphetamine Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 229960001344 methylphenidate Drugs 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010028347 Muscle twitching Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000701 neuroleptic effect Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 101150024767 arnT gene Proteins 0.000 description 4
- 239000003693 atypical antipsychotic agent Substances 0.000 description 4
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 4
- 230000035929 gnawing Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000002903 catalepsic effect Effects 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003176 neuroleptic agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NHAYOWZTQYFYOF-UHFFFAOYSA-N C(C)O.C(CC)OC(=O)C1=CC=C(O)C=C1.COC(=O)C1=CC=C(O)C=C1.OCC(O)CO Chemical compound C(C)O.C(CC)OC(=O)C1=CC=C(O)C=C1.COC(=O)C1=CC=C(O)C=C1.OCC(O)CO NHAYOWZTQYFYOF-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 101150039027 ampH gene Proteins 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001184 clopenthixol Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- -1 theophylline acetic acids Chemical class 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898908085A GB8908085D0 (en) | 1989-04-11 | 1989-04-11 | New therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE901051L IE901051L (en) | 1990-10-11 |
| IE81157B1 true IE81157B1 (en) | 2000-05-03 |
Family
ID=10654774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE105190A IE81157B1 (en) | 1989-04-11 | 1990-03-21 | Use of sertindole for the treatment of schizophrenia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5112838A (enExample) |
| EP (1) | EP0392959B1 (enExample) |
| JP (1) | JP2775191B2 (enExample) |
| KR (1) | KR920008703B1 (enExample) |
| AT (1) | ATE157005T1 (enExample) |
| AU (1) | AU621735B2 (enExample) |
| CA (1) | CA2014208C (enExample) |
| CY (1) | CY2082B1 (enExample) |
| DE (2) | DE19875011I2 (enExample) |
| DK (1) | DK0392959T3 (enExample) |
| GB (1) | GB8908085D0 (enExample) |
| IE (1) | IE81157B1 (enExample) |
| IL (1) | IL94021A (enExample) |
| NL (1) | NL980008I1 (enExample) |
| NZ (2) | NZ243765A (enExample) |
| SG (1) | SG48234A1 (enExample) |
| ZA (1) | ZA902785B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5238945A (en) * | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
| DK238190D0 (da) * | 1990-10-03 | 1990-10-03 | Lundbeck & Co As H | Depotderivater |
| US5643784A (en) * | 1990-12-04 | 1997-07-01 | H, Lundbeck A/S | Indan derivatives |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| DK206591D0 (da) * | 1991-12-23 | 1991-12-23 | Lundbeck & Co As H | Behandling af psykoser |
| DK8492D0 (da) * | 1992-01-23 | 1992-01-23 | Lundbeck & Co As H | Behandling af psykoser |
| DK123493D0 (da) * | 1993-11-01 | 1993-11-01 | Lundbeck & Co As H | Compounds |
| EP0906104A4 (en) * | 1996-03-25 | 2003-12-10 | Lilly Co Eli | PAIN TREATMENT PROCESS |
| ZA973433B (en) * | 1996-04-24 | 1997-12-10 | Shionogi & Co | A sertindole-containing preparation and a method for producing the same. |
| DK1026950T3 (da) * | 1997-10-27 | 2006-06-26 | Univ California | Behandling af skizofreni med ampakiner og neuroleptika |
| GB9805716D0 (en) * | 1998-03-17 | 1998-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| US6489341B1 (en) | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
| FR2802101B1 (fr) | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
| US20040023951A1 (en) * | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| DE60239634D1 (de) * | 2001-12-10 | 2011-05-12 | Novartis Ag | Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen |
| MXPA04009365A (es) * | 2002-03-27 | 2005-01-25 | Lundbeck & Co As H | Metodo para la manufactura de sertindol. |
| CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| EP1737473A4 (en) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | COMBINATIONS OF LITHIUM AND USES THEREOF |
| MXPA06013163A (es) * | 2004-05-11 | 2007-02-13 | Pfizer Prod Inc | Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b. |
| MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| AR049646A1 (es) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| DE602005008084D1 (de) * | 2004-08-24 | 2008-08-21 | Janssen Pharmaceutica Nv | Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate |
| KR20080012360A (ko) * | 2005-05-20 | 2008-02-11 | 얀센 파마슈티카 엔.브이. | 설파미드 유도체의 제조 방법 |
| US20070212412A1 (en) * | 2005-09-08 | 2007-09-13 | H. Lundbeck A/S | Stable solid formulation of sertindole |
| US20070155824A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
| US20070191450A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder |
| US20070191451A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents |
| US20070191460A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis |
| EA200870556A1 (ru) * | 2006-05-19 | 2009-06-30 | Янссен Фармацевтика Н.В. | Комбинированная терапия в лечении эпилепсии и родственных расстройств |
| TW200821296A (en) * | 2006-06-01 | 2008-05-16 | Lundbeck & Co As H | Use of sertindole for the preventive treatment of suicidal behaviour |
| EP2041304B1 (en) * | 2006-06-12 | 2011-09-07 | Hadasit Medical Research Services & Development Limited | Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication |
| PL2083811T3 (pl) | 2006-11-22 | 2017-05-31 | Clinical Research Associates, Llc | Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu |
| WO2008106144A2 (en) * | 2007-02-28 | 2008-09-04 | Nupathe Inc. | Implants for the treatment of psychiatric states |
| US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
| EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| EA018567B1 (ru) | 2008-06-23 | 2013-08-30 | Янссен Фармацевтика Нв | Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида |
| CA2727573A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| US8252801B1 (en) | 2009-06-03 | 2012-08-28 | Abbott Laboratories | Treatment of schizophrenia and related disorders |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4359468A (en) * | 1981-02-25 | 1982-11-16 | Boehringer Ingelheim Ltd. | Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones |
| IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| US4742057A (en) * | 1985-12-05 | 1988-05-03 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic thiazole compounds |
| ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
-
1989
- 1989-04-11 GB GB898908085A patent/GB8908085D0/en active Pending
-
1990
- 1990-03-21 IE IE105190A patent/IE81157B1/en not_active IP Right Cessation
- 1990-03-30 EP EP90610022A patent/EP0392959B1/en not_active Expired - Lifetime
- 1990-03-30 DE DE1998175011 patent/DE19875011I2/de active Active
- 1990-03-30 AT AT90610022T patent/ATE157005T1/de active
- 1990-03-30 SG SG1996008153A patent/SG48234A1/en unknown
- 1990-03-30 DK DK90610022T patent/DK0392959T3/da active
- 1990-03-30 DE DE69031290T patent/DE69031290T2/de not_active Expired - Lifetime
- 1990-04-03 NZ NZ243765A patent/NZ243765A/en unknown
- 1990-04-03 NZ NZ233179A patent/NZ233179A/en unknown
- 1990-04-05 IL IL9402190A patent/IL94021A/en active Protection Beyond IP Right Term
- 1990-04-06 JP JP2090502A patent/JP2775191B2/ja not_active Expired - Lifetime
- 1990-04-09 CA CA002014208A patent/CA2014208C/en not_active Expired - Lifetime
- 1990-04-10 AU AU53037/90A patent/AU621735B2/en not_active Expired
- 1990-04-11 US US07/508,240 patent/US5112838A/en not_active Expired - Lifetime
- 1990-04-11 KR KR1019900004984A patent/KR920008703B1/ko not_active Expired
- 1990-04-11 ZA ZA902785A patent/ZA902785B/xx unknown
-
1998
- 1998-02-18 NL NL980008C patent/NL980008I1/nl unknown
- 1998-10-16 CY CY9802082A patent/CY2082B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0392959A3 (en) | 1992-05-06 |
| IE901051L (en) | 1990-10-11 |
| AU621735B2 (en) | 1992-03-19 |
| NZ243765A (en) | 1997-09-22 |
| JP2775191B2 (ja) | 1998-07-16 |
| US5112838A (en) | 1992-05-12 |
| DK0392959T3 (da) | 1999-03-29 |
| AU5303790A (en) | 1990-10-18 |
| EP0392959B1 (en) | 1997-08-20 |
| CA2014208C (en) | 1996-03-19 |
| KR900015730A (ko) | 1990-11-10 |
| GB8908085D0 (en) | 1989-05-24 |
| ZA902785B (en) | 1991-06-26 |
| DE69031290D1 (de) | 1997-09-25 |
| CY2082B1 (en) | 1998-10-16 |
| IL94021A (en) | 1994-01-25 |
| CA2014208A1 (en) | 1990-10-11 |
| JPH02290872A (ja) | 1990-11-30 |
| NL980008I1 (nl) | 1998-05-06 |
| DE19875011I2 (de) | 2004-07-01 |
| DE69031290T2 (de) | 1998-01-02 |
| NZ233179A (en) | 1996-12-20 |
| IL94021A0 (enExample) | 1991-01-31 |
| HK1002825A1 (en) | 1998-09-18 |
| KR920008703B1 (ko) | 1992-10-08 |
| EP0392959A2 (en) | 1990-10-17 |
| ATE157005T1 (de) | 1997-09-15 |
| SG48234A1 (en) | 1998-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5112838A (en) | Method of treating psychoses in human beings with the atypical neuroleptic 5-chloro-1-(4-fluorophenyl)-3-(1-(2-(2-imidazolidinon-1-yl)ethyl-4-piperidyl)1h-indole | |
| US5238945A (en) | Method of treating psychoses | |
| EP1045693B1 (en) | Aminophenoxyacetic acid derivatives as neuroprotectants | |
| US6114356A (en) | Method for treating gastrointestinal disorders using (+) norcisapride | |
| US6649183B2 (en) | Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron | |
| US6242465B1 (en) | Compositions of optically pure (+) norcisapride | |
| JP2021167279A (ja) | ミトコンドリア病の予防または治療のための医薬組成物 | |
| US5281594A (en) | Substituted 1-(alkoxyphenyl)piperazines with ons and antihypertensive activity | |
| HK1002825B (en) | Use of sertindole for the treatment of schizophrenia | |
| AU668537B2 (en) | Use of arylindole derivatives for the treatment of psychoses | |
| WO1993014758A1 (en) | Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses | |
| GB2362826A (en) | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist | |
| US20030212109A1 (en) | Pharmaceutical compositions and their use | |
| EP1435238A1 (en) | Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Request for grant of supplementary protection certificate |
Free format text: SPC009/2000, 28062000 |
|
| SPCX | Correction of an erratum in the gazette concerning an spc |
Free format text: IN GAZETTE OF 20000823, REQUEST OF GRANT OF SPC WAS INCORRECTLY ADVERTISED FOR SPC009/2000; CORRECTSPC NO IS: SPC010/2000. Spc suppl protection certif: SPC010/2000 Filing date: 20000628 |
|
| SPCR | Supplementary protection certificate rejected |
Spc suppl protection certif: SPC010/2000 Filing date: 20000628 |
|
| MK9A | Patent expired |